 Brandon Mcmahon
Concepts (228)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombosis | 5 | 2015 | 319 | 1.390 |
Why?
| | Myeloproliferative Disorders | 8 | 2022 | 27 | 1.350 |
Why?
| | Urokinase-Type Plasminogen Activator | 4 | 2015 | 30 | 1.080 |
Why?
| | Plasminogen Activator Inhibitor 1 | 3 | 2015 | 87 | 0.970 |
Why?
| | Thrombocytopenia | 3 | 2016 | 188 | 0.940 |
Why?
| | Neoplasms | 8 | 2020 | 2340 | 0.910 |
Why?
| | Hemorrhage | 5 | 2018 | 673 | 0.880 |
Why?
| | Anticoagulants | 4 | 2018 | 587 | 0.880 |
Why?
| | Plasminogen | 3 | 2013 | 35 | 0.760 |
Why?
| | Fibrinolysin | 2 | 2013 | 19 | 0.750 |
Why?
| | Receptors, Urokinase Plasminogen Activator | 2 | 2015 | 14 | 0.570 |
Why?
| | Anemia, Pernicious | 1 | 2016 | 9 | 0.540 |
Why?
| | Pancytopenia | 1 | 2016 | 7 | 0.540 |
Why?
| | Hypothyroidism | 1 | 2016 | 68 | 0.520 |
Why?
| | Neoplasm Proteins | 2 | 2009 | 409 | 0.510 |
Why?
| | Myelodysplastic Syndromes | 2 | 2016 | 120 | 0.500 |
Why?
| | Unnecessary Procedures | 1 | 2014 | 48 | 0.460 |
Why?
| | Tissue Inhibitor of Metalloproteinase-2 | 1 | 2013 | 12 | 0.430 |
Why?
| | Heparin | 1 | 2014 | 236 | 0.430 |
Why?
| | Liver Cirrhosis | 1 | 2014 | 249 | 0.410 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 837 | 0.400 |
Why?
| | Thrombophilia | 2 | 2009 | 70 | 0.390 |
Why?
| | Blood Platelets | 1 | 2014 | 397 | 0.380 |
Why?
| | Polycythemia Vera | 4 | 2022 | 14 | 0.370 |
Why?
| | Fibrinolysis | 2 | 2009 | 175 | 0.350 |
Why?
| | Medical Oncology | 4 | 2022 | 241 | 0.350 |
Why?
| | Biomarkers, Tumor | 2 | 2018 | 1080 | 0.340 |
Why?
| | Interferon Type I | 3 | 2015 | 131 | 0.320 |
Why?
| | Tissue Plasminogen Activator | 2 | 2009 | 245 | 0.290 |
Why?
| | Antineoplastic Agents | 5 | 2018 | 2009 | 0.290 |
Why?
| | Intracellular Signaling Peptides and Proteins | 3 | 2015 | 410 | 0.280 |
Why?
| | Primary Myelofibrosis | 2 | 2022 | 10 | 0.240 |
Why?
| | Thrombocythemia, Essential | 1 | 2022 | 7 | 0.210 |
Why?
| | Interferon-alpha | 2 | 2014 | 193 | 0.210 |
Why?
| | MAP Kinase Signaling System | 2 | 2015 | 304 | 0.200 |
Why?
| | Humans | 31 | 2022 | 125131 | 0.200 |
Why?
| | Mastocytosis, Systemic | 1 | 2018 | 4 | 0.160 |
Why?
| | Eosinophilia | 1 | 2020 | 185 | 0.160 |
Why?
| | Chicago | 2 | 2016 | 46 | 0.150 |
Why?
| | Neovascularization, Pathologic | 2 | 2009 | 287 | 0.140 |
Why?
| | Janus Kinase 2 | 2 | 2015 | 35 | 0.140 |
Why?
| | Risk Factors | 4 | 2015 | 9549 | 0.140 |
Why?
| | Neoplasm Metastasis | 2 | 2009 | 573 | 0.140 |
Why?
| | Anaphylaxis | 1 | 2018 | 147 | 0.130 |
Why?
| | Philadelphia Chromosome | 1 | 2016 | 15 | 0.130 |
Why?
| | Vitamin B 12 Deficiency | 1 | 2016 | 75 | 0.130 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2016 | 57 | 0.130 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2015 | 61 | 0.130 |
Why?
| | Vitamin B 12 | 1 | 2016 | 116 | 0.130 |
Why?
| | Thienamycins | 1 | 2015 | 4 | 0.130 |
Why?
| | Piperacillin | 1 | 2015 | 8 | 0.120 |
Why?
| | Inactivation, Metabolic | 1 | 2015 | 11 | 0.120 |
Why?
| | Anemia, Hemolytic | 1 | 2015 | 18 | 0.120 |
Why?
| | Venous Thromboembolism | 1 | 2018 | 236 | 0.120 |
Why?
| | Age Factors | 4 | 2015 | 3152 | 0.120 |
Why?
| | Vitamin K | 1 | 2015 | 45 | 0.120 |
Why?
| | Biomarkers | 2 | 2016 | 3736 | 0.120 |
Why?
| | Cell Movement | 2 | 2009 | 913 | 0.120 |
Why?
| | False Positive Reactions | 1 | 2014 | 122 | 0.120 |
Why?
| | Hemostasis | 1 | 2014 | 71 | 0.120 |
Why?
| | Signal Transduction | 4 | 2016 | 4809 | 0.120 |
Why?
| | Patient Care Team | 1 | 2018 | 546 | 0.110 |
Why?
| | Drug Hypersensitivity | 1 | 2015 | 86 | 0.110 |
Why?
| | Bone Marrow Neoplasms | 1 | 2013 | 3 | 0.110 |
Why?
| | Drug Monitoring | 1 | 2015 | 186 | 0.110 |
Why?
| | Pyrazoles | 2 | 2016 | 380 | 0.110 |
Why?
| | Blood Transfusion | 1 | 2016 | 312 | 0.110 |
Why?
| | Pseudomonas Infections | 1 | 2015 | 192 | 0.110 |
Why?
| | Academic Medical Centers | 1 | 2016 | 447 | 0.110 |
Why?
| | Chi-Square Distribution | 1 | 2014 | 558 | 0.110 |
Why?
| | Thrombocytosis | 1 | 2012 | 8 | 0.110 |
Why?
| | Leukocytosis | 1 | 2012 | 36 | 0.110 |
Why?
| | Interferon-beta | 1 | 2013 | 87 | 0.110 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2012 | 23 | 0.110 |
Why?
| | Predictive Value of Tests | 2 | 2015 | 1992 | 0.100 |
Why?
| | Administration, Oral | 1 | 2015 | 785 | 0.100 |
Why?
| | Annexin A2 | 2 | 2009 | 12 | 0.100 |
Why?
| | Prognosis | 3 | 2016 | 3616 | 0.100 |
Why?
| | Antibodies | 1 | 2014 | 396 | 0.100 |
Why?
| | Nitriles | 1 | 2012 | 159 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 879 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2015 | 1196 | 0.100 |
Why?
| | Adult | 8 | 2022 | 33167 | 0.100 |
Why?
| | RNA-Binding Proteins | 1 | 2014 | 394 | 0.090 |
Why?
| | Respiratory Tract Infections | 1 | 2015 | 335 | 0.090 |
Why?
| | Phosphoproteins | 1 | 2012 | 320 | 0.090 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2016 | 544 | 0.090 |
Why?
| | Nuclear Proteins | 1 | 2014 | 614 | 0.090 |
Why?
| | Pyrimidines | 1 | 2012 | 391 | 0.080 |
Why?
| | Carrier Proteins | 1 | 2014 | 743 | 0.080 |
Why?
| | Apoptosis | 2 | 2009 | 2553 | 0.080 |
Why?
| | Leukemia, Promyelocytic, Acute | 1 | 2009 | 13 | 0.080 |
Why?
| | Disease Progression | 3 | 2015 | 2577 | 0.080 |
Why?
| | Cryoglobulins | 1 | 2009 | 7 | 0.080 |
Why?
| | Plasminogen Inactivators | 1 | 2009 | 3 | 0.080 |
Why?
| | Carboxypeptidase B2 | 1 | 2009 | 5 | 0.080 |
Why?
| | Mutation | 3 | 2018 | 3520 | 0.080 |
Why?
| | Blood Group Antigens | 1 | 2009 | 16 | 0.080 |
Why?
| | Anemia, Hemolytic, Autoimmune | 1 | 2009 | 14 | 0.080 |
Why?
| | Receptors, Peptide | 1 | 2009 | 24 | 0.080 |
Why?
| | Cerebral Infarction | 1 | 2009 | 44 | 0.080 |
Why?
| | Edetic Acid | 1 | 2008 | 47 | 0.080 |
Why?
| | Factor VII | 1 | 2008 | 27 | 0.080 |
Why?
| | Factor VIII | 1 | 2008 | 56 | 0.080 |
Why?
| | Nerve Tissue Proteins | 1 | 2012 | 563 | 0.080 |
Why?
| | von Willebrand Factor | 1 | 2008 | 60 | 0.080 |
Why?
| | Multiple Organ Failure | 1 | 2009 | 167 | 0.080 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2020 | 181 | 0.070 |
Why?
| | Time Factors | 2 | 2018 | 6780 | 0.070 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1376 | 0.070 |
Why?
| | Animals | 7 | 2016 | 34345 | 0.070 |
Why?
| | Immunoglobulin M | 1 | 2009 | 253 | 0.070 |
Why?
| | Neoplasm Invasiveness | 1 | 2009 | 472 | 0.070 |
Why?
| | Practice Patterns, Physicians' | 1 | 2016 | 1280 | 0.070 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2009 | 371 | 0.070 |
Why?
| | Cell Division | 1 | 2009 | 796 | 0.070 |
Why?
| | Membrane Proteins | 1 | 2012 | 1089 | 0.070 |
Why?
| | Blood Coagulation Disorders | 1 | 2009 | 220 | 0.070 |
Why?
| | Retrospective Studies | 4 | 2016 | 13708 | 0.060 |
Why?
| | Intestines | 1 | 2009 | 337 | 0.060 |
Why?
| | Ischemia | 1 | 2009 | 383 | 0.060 |
Why?
| | Cystic Fibrosis | 1 | 2015 | 990 | 0.060 |
Why?
| | Cytokines | 2 | 2014 | 1927 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1559 | 0.060 |
Why?
| | Female | 7 | 2016 | 64889 | 0.060 |
Why?
| | Mice | 5 | 2014 | 15984 | 0.060 |
Why?
| | Janus Kinases | 2 | 2016 | 14 | 0.060 |
Why?
| | Immunosuppressive Agents | 1 | 2009 | 693 | 0.060 |
Why?
| | Erythroid Cells | 2 | 2015 | 9 | 0.060 |
Why?
| | Molecular Targeted Therapy | 2 | 2018 | 361 | 0.060 |
Why?
| | Societies, Medical | 2 | 2018 | 754 | 0.060 |
Why?
| | Aging | 1 | 2014 | 1706 | 0.060 |
Why?
| | Aged | 4 | 2016 | 20859 | 0.060 |
Why?
| | Treatment Outcome | 4 | 2018 | 9790 | 0.050 |
Why?
| | Middle Aged | 5 | 2016 | 29112 | 0.050 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 2 | 2015 | 292 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2009 | 1300 | 0.050 |
Why?
| | Autoantibodies | 1 | 2009 | 1382 | 0.050 |
Why?
| | Survival Analysis | 2 | 2018 | 1341 | 0.050 |
Why?
| | Combined Modality Therapy | 2 | 2017 | 1200 | 0.050 |
Why?
| | Hematopoietic Stem Cells | 2 | 2014 | 366 | 0.040 |
Why?
| | Phosphorylation | 2 | 2014 | 1694 | 0.040 |
Why?
| | Male | 6 | 2016 | 60792 | 0.040 |
Why?
| | Histamine Antagonists | 1 | 2018 | 15 | 0.040 |
Why?
| | mRNA Cleavage and Polyadenylation Factors | 1 | 2018 | 28 | 0.040 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2018 | 42 | 0.040 |
Why?
| | Fibroblasts | 2 | 2014 | 859 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2018 | 61 | 0.040 |
Why?
| | Mast Cells | 1 | 2018 | 115 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2018 | 286 | 0.040 |
Why?
| | Prevalence | 2 | 2015 | 2488 | 0.040 |
Why?
| | Cell Line, Tumor | 2 | 2015 | 2913 | 0.040 |
Why?
| | Transplantation, Homologous | 1 | 2018 | 434 | 0.040 |
Why?
| | Bone Marrow | 1 | 2018 | 259 | 0.040 |
Why?
| | Receptors, Thrombopoietin | 1 | 2016 | 7 | 0.030 |
Why?
| | Thrombopoietin | 1 | 2016 | 7 | 0.030 |
Why?
| | Benzoates | 1 | 2016 | 42 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2015 | 4159 | 0.030 |
Why?
| | Hydrazines | 1 | 2016 | 35 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 760 | 0.030 |
Why?
| | Receptors, Fc | 1 | 2016 | 48 | 0.030 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2016 | 87 | 0.030 |
Why?
| | General Practice | 1 | 2016 | 26 | 0.030 |
Why?
| | Platelet Count | 1 | 2015 | 89 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 1006 | 0.030 |
Why?
| | Autophagy-Related Protein-1 Homolog | 1 | 2015 | 8 | 0.030 |
Why?
| | Azacitidine | 1 | 2016 | 130 | 0.030 |
Why?
| | Immunologic Tests | 1 | 2015 | 16 | 0.030 |
Why?
| | Interferon Regulatory Factors | 1 | 2015 | 32 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 1093 | 0.030 |
Why?
| | Interferons | 1 | 2016 | 157 | 0.030 |
Why?
| | Response Elements | 1 | 2015 | 87 | 0.030 |
Why?
| | Nuclear Cap-Binding Protein Complex | 1 | 2014 | 1 | 0.030 |
Why?
| | Patient Selection | 1 | 2018 | 725 | 0.030 |
Why?
| | Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2014 | 13 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2016 | 6936 | 0.030 |
Why?
| | Ubiquitins | 1 | 2014 | 34 | 0.030 |
Why?
| | Guanosine | 1 | 2014 | 40 | 0.030 |
Why?
| | Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2014 | 28 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2026 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 113 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2016 | 574 | 0.030 |
Why?
| | Microbial Sensitivity Tests | 1 | 2015 | 310 | 0.030 |
Why?
| | Medication Adherence | 1 | 2018 | 582 | 0.030 |
Why?
| | Mutation, Missense | 1 | 2015 | 305 | 0.030 |
Why?
| | Risk | 1 | 2016 | 896 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 2016 | 658 | 0.030 |
Why?
| | Eukaryotic Initiation Factor-4E | 1 | 2013 | 27 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2018 | 552 | 0.030 |
Why?
| | Cell Line, Transformed | 1 | 2013 | 143 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1324 | 0.030 |
Why?
| | U937 Cells | 1 | 2012 | 29 | 0.030 |
Why?
| | Aspirin | 1 | 2015 | 348 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2014 | 317 | 0.030 |
Why?
| | Hospitalists | 1 | 2016 | 181 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1561 | 0.030 |
Why?
| | Embryo, Mammalian | 1 | 2012 | 226 | 0.020 |
Why?
| | Patient Outcome Assessment | 1 | 2013 | 132 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2016 | 557 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 2040 | 0.020 |
Why?
| | Leukemia | 1 | 2013 | 212 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2016 | 832 | 0.020 |
Why?
| | Vascular Diseases | 1 | 2013 | 251 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2012 | 400 | 0.020 |
Why?
| | Splanchnic Circulation | 1 | 2009 | 13 | 0.020 |
Why?
| | Infarction | 1 | 2009 | 16 | 0.020 |
Why?
| | Plasmapheresis | 1 | 2009 | 24 | 0.020 |
Why?
| | Blood Specimen Collection | 1 | 2008 | 34 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2009 | 191 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 84 | 0.020 |
Why?
| | Giant Cell Arteritis | 1 | 2009 | 48 | 0.020 |
Why?
| | Immunoassay | 1 | 2008 | 104 | 0.020 |
Why?
| | Tretinoin | 1 | 2009 | 127 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2009 | 299 | 0.020 |
Why?
| | Rituximab | 1 | 2009 | 159 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3274 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1442 | 0.020 |
Why?
| | Spleen | 1 | 2009 | 513 | 0.020 |
Why?
| | Hospitalization | 1 | 2016 | 1960 | 0.020 |
Why?
| | Plasma | 1 | 2008 | 224 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2012 | 2736 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2013 | 1778 | 0.020 |
Why?
| | Internship and Residency | 1 | 2016 | 1083 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 4854 | 0.020 |
Why?
| | United States | 1 | 2018 | 13613 | 0.010 |
Why?
| | Kidney | 1 | 2009 | 1379 | 0.010 |
Why?
| | Liver | 1 | 2009 | 1872 | 0.010 |
Why?
| | Adolescent | 1 | 2015 | 19411 | 0.010 |
Why?
|
|
Mcmahon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|